Jazz Pharmaceuticals (NASDAQ:JAZZ) Director Mark Douglas Smith Sells 1,157 Shares of Stock

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Director Mark Douglas Smith sold 1,157 shares of the business’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $230.55, for a total value of $266,746.35. Following the transaction, the director owned 9,680 shares in the company, valued at approximately $2,231,724. This trade represents a 10.68% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jazz Pharmaceuticals Stock Performance

Shares of Jazz Pharmaceuticals stock opened at $226.93 on Thursday. The company has a 50 day moving average price of $220.08 and a 200 day moving average price of $189.96. The firm has a market capitalization of $14.26 billion, a P/E ratio of -11,340.83, a PEG ratio of 0.20 and a beta of 0.32. The company has a quick ratio of 1.85, a current ratio of 2.04 and a debt-to-equity ratio of 0.95. Jazz Pharmaceuticals PLC has a 52 week low of $105.00 and a 52 week high of $243.32.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share for the quarter. Jazz Pharmaceuticals had a net margin of 0.66% and a return on equity of 14.56%. The company had revenue of $1.07 billion for the quarter. Sell-side analysts expect that Jazz Pharmaceuticals PLC will post 22.09 EPS for the current year.

Analyst Ratings Changes

JAZZ has been the subject of a number of research analyst reports. Wells Fargo & Company raised their target price on Jazz Pharmaceuticals from $250.00 to $265.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 6th. Sanford C. Bernstein reiterated a “market perform” rating on shares of Jazz Pharmaceuticals in a research note on Tuesday, June 9th. Royal Bank Of Canada increased their price objective on Jazz Pharmaceuticals from $195.00 to $258.00 and gave the company an “outperform” rating in a report on Wednesday, May 6th. Robert W. Baird set a $252.00 price objective on Jazz Pharmaceuticals in a research note on Wednesday, May 6th. Finally, TD Cowen lifted their target price on Jazz Pharmaceuticals from $220.00 to $275.00 and gave the stock a “buy” rating in a report on Wednesday, May 6th. Sixteen analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $246.06.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the business. NewEdge Advisors LLC grew its position in Jazz Pharmaceuticals by 132.6% during the 1st quarter. NewEdge Advisors LLC now owns 1,975 shares of the specialty pharmaceutical company’s stock worth $373,000 after purchasing an additional 1,126 shares during the period. Glenmede Trust Co. NA lifted its holdings in shares of Jazz Pharmaceuticals by 1.9% in the 1st quarter. Glenmede Trust Co. NA now owns 7,819 shares of the specialty pharmaceutical company’s stock valued at $1,478,000 after buying an additional 146 shares during the period. Bank of America Corp DE boosted its stake in shares of Jazz Pharmaceuticals by 10.9% in the first quarter. Bank of America Corp DE now owns 1,014,800 shares of the specialty pharmaceutical company’s stock worth $191,848,000 after buying an additional 99,656 shares during the last quarter. Tri Locum Partners LP purchased a new stake in shares of Jazz Pharmaceuticals in the first quarter worth about $29,995,000. Finally, Amundi grew its holdings in Jazz Pharmaceuticals by 2,445.3% during the first quarter. Amundi now owns 55,640 shares of the specialty pharmaceutical company’s stock worth $10,519,000 after acquiring an additional 53,454 shares during the period. 89.14% of the stock is owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.